Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Sees Large Increase in Short Interest

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) was the target of a significant growth in short interest in February. As of February 15th, there was short interest totalling 576,400 shares, a growth of 149.0% from the January 31st total of 231,500 shares. Based on an average daily volume of 281,000 shares, the days-to-cover ratio is currently 2.1 days.

Wall Street Analyst Weigh In

Separately, StockNews.com downgraded shares of Oramed Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, February 19th.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. World Equity Group Inc. acquired a new stake in Oramed Pharmaceuticals during the fourth quarter worth about $48,000. XTX Topco Ltd boosted its position in Oramed Pharmaceuticals by 59.7% in the 3rd quarter. XTX Topco Ltd now owns 24,716 shares of the biotechnology company’s stock worth $60,000 after purchasing an additional 9,242 shares in the last quarter. Marquette Asset Management LLC acquired a new stake in shares of Oramed Pharmaceuticals during the 4th quarter worth approximately $81,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Oramed Pharmaceuticals during the 3rd quarter valued at approximately $272,000. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Oramed Pharmaceuticals by 143.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 118,995 shares of the biotechnology company’s stock valued at $288,000 after purchasing an additional 70,190 shares during the period. 12.73% of the stock is owned by institutional investors and hedge funds.

Oramed Pharmaceuticals Stock Down 0.5 %

Shares of NASDAQ ORMP traded down $0.01 during trading hours on Friday, hitting $2.09. 58,677 shares of the stock were exchanged, compared to its average volume of 323,366. The company has a market cap of $84.25 million, a PE ratio of 19.00 and a beta of 1.66. Oramed Pharmaceuticals has a 12 month low of $2.00 and a 12 month high of $3.48. The firm has a fifty day moving average price of $2.31 and a 200-day moving average price of $2.36.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.